Pharmacy Learning Network Case Vignettes

The Role of Health-System Pharmacists in Prevention and Treatment: Focus on RSV and VTE

Jointly sponsored by North American Center for Continuing Medical Education, LLC and Lancer Solutions, LLC

Learning Objectives

After completing this activity, participants should be better able to:

• Identify the incidence and burden of respiratory syncytial virus (RSV)-related infection in the hospital, including long-term complications
• Describe strategies to identify infants and young children at high risk for RSV-related infection, factoring in evidence-based guidelines and seasonal and regional surveillance data
• Summarize the benefits and limitations of current methods for RSV prevention and management
• Apply evidence-based guidelines to optimize RSV prevention in high-risk infants and young children in the hospital setting and postdischarge

Independent Clinical Reviewer: Lea S. Eiland, PharmD, BCPS, Associate Clinical Professor of Pharmacy Practice, Auburn University, Harrison School of Pharmacy, Auburn, Alabama

Learning Objectives

After completing this activity, participants should be better able to:

• Summarize current evidence-based guidelines and quality measures for venous thromboembolism (VTE) risk stratification, prophylaxis, and management
• Explain the increased risk of VTE and/or complications of VTE management associated with frequent comorbidities, such as cancer, renal insufficiency, and older age
• Implement effective VTE management protocols for special patient populations, including appropriate dosing and monitoring strategies
• Apply current VTE guidelines and measures to improve outcomes across the continuum of care

Independent Clinical Reviewer: Wendy Cantrell, PharmD, BCPS, BCNSP, CACP, Cardiology Clinical Specialist, University Medical Center of Southern Nevada, University of Southern Nevada College of Pharmacy, Las Vegas, Nevada

Target Audience

This activity is designed for health-system pharmacists.

Activity Overview

To receive a statement of credit, you must:

• Review the full content of the activity
• Successfully complete all questions throughout the case activity (75% or higher)
• You will have three (3) opportunities to successfully complete the activity

Your statement of credit will be issued immediately upon successful completion of the activity and submission of the evaluation form.

This educational activity is an application-based activity.

There is no fee associated with this activity.

Release Date: September 30, 2009

Expiration Date: September 30, 2010

Estimated time to complete: 1.25 hours

If you have any questions regarding this activity, please contact:

Lance M. Nicholls, PharmD
President
Lancer Solutions, LLC
25 Tamarack Drive
New Milford, CT 06776

+1.860.799.0523 (Office)
+1.203.616.5137 (Fax)
E-mail: lancenicholls@lancersolutions.com

Hardware/Software Requirements

All educational activities are accessible via a computer with 650 MHz PC, 128 MB RAM, Windows or MAC operating system, Internet Explorer, Netscape or Safari browsers. Windows Media Player, sound card, and speakers are required for streamed audio. Flash Player, sound card, and speakers are required for video programs. A PDF reader is required for print publications. Please direct technical questions to webmaster@naccme.com.

CPE Accreditation

North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is approved for 1.25 contact hours (0.125 CEUs) of continuing pharmacy education (UAN 276-999-09-024-H01-P).

Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by NACCME may contact John Savage, Director, Medical Education, NACCME, in writing at 300 Rike Drive, Suite A, Millstone Township, NJ 08535, or by e-mail at jsavage@naccme.com. The Director of Medical Education will review the grievance and respond within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Vice President, Medical Education, NACCME, may be made for a second level of review.

Planning Committee

The planning committee comprises Wendy Cantrell, PharmD, BCPS, BCNSP, CACP, Paul P. Dobesh, PharmD, FCCP, BCPS, Lea S. Eiland, PharmD, BCPS, Elizabeth Farrington, PharmD, FCCP, FCCM, BCPS, Sherry Luedtke, PharmD, Ann Wittkowsky, PharmD; and Kristin Dickie, Mary Johnson, Rich Keenan, Randy Robbin, and John Savage, NACCME; and Lance Nicholls, PharmD, Lancer Solutions, LLC.

Financial Disclosure and Conflicts of Interest

According to the disclosure policy of NACCME and Lancer Solutions, LLC, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of NACCME, and Lancer Solutions, LLC to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.

The faculty has reported the following:

Dr. Dobesh: Consultant—sanofi-aventis U.S., The Medicines Company; Promotional speakers bureau—sanofi-aventis U.S.
Dr. Eiland: Promotional speakers bureau [spouse]—Cubist, Wyeth Pharmaceuticals
Dr. Luedtke: Promotional speakers bureau—Discovery Lab
Dr. Wittkowsky: Consultant—Roche Diagnostics, sanofi-aventis U.S.
Dr. Cantrell and Dr. Farrington have disclosed no relevant financial relationships with any commercial interests.

Ms. Dickie, Ms. Johnson, Mr. Keenan, Dr. Nicholls, Mr. Robbin, and Mr. Savage, have disclosed no relevant financial relationships with any commercial interests.

NACCME requires faculty to inform participants whenever off-label/unapproved uses of drugs and/or devices are discussed in their presentation.

The faculty has disclosed the following off-label/unapproved use(s) of drugs and/or devices will be discussed: fondaparinux in the prevention of DVT in medically-ill patients, palivizumab in the prevention of nosocomial infections.

Privacy Policy

NACCME and Lancer Solutions, LLC protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. We and our joint sponsors will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency. We also maintain physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

Copyright © 2009 by North American Center for Continuing Medical Education, LLC, and Lancer Solutions, LLC. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from North American Center for Continuing Medical Education and Lancer Solutions, LLC

Grant Support

Supported by educational grants from MedImmune and sanofi-aventis U.S.